Associated Papers
Adult genomic medicine: lessons from a multisite study of 2700 patients.
Bakur K et al.
Genome Medicine, 2025
41024252 (PubMed )
Supplement: 13073_2025_1529_MOESM1_ESM.xlsx › Sheet1
Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting.
Kubota Y et al.
Nature Communications, 2024
38418452 (PubMed )
Supplement: 41467_2024_46134_MOESM5_ESM.xlsx › Supplementary_Data_2
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
González-López O et al.
Cancers, 2022
Genetic basis of myelodysplastic syndromes.
Ogawa S
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 2020
Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome.
Duncavage EJ et al.
Leukemia, 2016
27573557 (PubMed )
Supplement: NIHMS801589-supplement-2.xlsx › Sheet1
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.
Palomero T et al.
Nature Genetics, 2014
24413734 (PubMed )
Supplement: NIHMS549899-supplement-2.xlsx › Supplementary_Table_5
[IDH1/2 gene mutations in myelodysplastic syndromes].
Yoshida K et al.
[rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 2012
Select a paper to view details